📄 Extracted Text (234 words)
might saddle state Medicaid programs with steep costs. US is the only major health-care market
remaining without any meaningful drug price controls -- increased risk for the sector once the
Congress gets involved, especially if focused primarily on pricing.
Description Trade Date Quantity Last Prices Unit Cost Market Value Unrealized G/L
SANGAIIO BIOSCIENCES 05/28/2013 50,000.00 5 19.80 $ 8.44 $ 990,000.00 $ 567,786.00
BIOGEN 02/14/2012 2,095.30 $ 312.60 $ 119.55 $ 654,897.00 $ 404;142.05
FOUNDATION MEDICINE 01/13/2014 25,000.00 $ 36.40 $ 27.51 910,000.00 $ 222,336.50
GILEAD SCIENCES INC 2/5/14, 3/7/14 8,100.30 $ 72.13 $ 79.41 $ 584,253.00 $ (58,951.00)
ARIAD PHARMACEUTICALS 2/14/12, 1/24/13 16,535.00 5 7.60 $ 17.60 $ 125,666.00 $ (165,331.40)
Total Biotec $3,264,816.00 $ 970,282.15
Nasda. Biotech Index -1 r Price Histo
NBI
On 24 Mar 2537.52 2587.92 L 2434.16 2499.44
NBI Index 95) Save As 99 Actions - 97) Edit - 9$ Table Line Chart
03;25/2013 01;2512014 It!. corrpare <7.,
10 30 1M oti .70 3Y SY Max Daily • C Security/Stuffy Event O
• Track Annotate 'fr2 News O, Zoom
2800
o• Last Price 2499.44
T High on 02/25/14 2854.26 7600
+- Average 2155.07 2499.44
1 Low on 03/25/13 1619.16 2400
2200
2000
1800
1600
on Volume 83.0411
SMAVG (15) . 62.329M
I
IflHIIiuiiww 0
Jun Sep Dec Mar
2013 2014
Ariad - 1yr Price History
CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) DB-SDNY-0 111022
CONFIDENTIAL SDNY_GM_00257206
EFTA01453440
ℹ️ Document Details
SHA-256
658305f040f78704eee7a18b757fd595773e0051755d801923d83aff2c3e50c1
Bates Number
EFTA01453440
Dataset
DataSet-10
Document Type
document
Pages
1
Comments 0